Legacy Capital Partners Inc. purchased a new position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 5,250 shares of the medical research company’s stock, valued at approximately $799,000.
Several other large investors have also modified their holdings of the company. Glassman Wealth Services raised its stake in shares of Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock worth $110,000 after buying an additional 600 shares during the period. Oakworth Capital Inc. raised its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the period. Integrated Wealth Management raised its stake in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares during the period. Delta Asset Management LLC TN raised its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the period. Finally, Capital Advisors Ltd. LLC raised its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the period. 79.15% of the stock is owned by hedge funds and other institutional investors.
Amgen Inc. (NASDAQ:AMGN) traded down 0.930% during trading on Monday, reaching $173.174. The company had a trading volume of 578,164 shares. The firm has a 50-day moving average of $172.09 and a 200-day moving average of $160.08. The stock has a market capitalization of $129.60 billion, a price-to-earnings ratio of 17.721 and a beta of 0.87. Amgen Inc. has a 1-year low of $130.09 and a 1-year high of $176.85.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. During the same period last year, the firm earned $2.57 earnings per share. Amgen’s quarterly revenue was up 5.9% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post $11.36 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were issued a dividend of $1.00 per share. This represents a $4.00 annualized dividend and a dividend yield of 2.29%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s payout ratio is 40.90%.
Several research analysts have recently commented on the company. Vetr lowered Amgen from a “hold” rating to a “sell” rating and set a $166.35 price target for the company. in a research report on Monday, August 1st. Goldman Sachs Group Inc. reissued a “buy” rating and issued a $204.00 price target on shares of Amgen in a research report on Thursday, September 8th. Cowen and Company reissued a “buy” rating on shares of Amgen in a research report on Monday, September 19th. Jefferies Group reissued a “buy” rating and issued a $187.00 price target on shares of Amgen in a research report on Wednesday, July 13th. Finally, Piper Jaffray Cos. reissued a “buy” rating and issued a $193.00 price target on shares of Amgen in a research report on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the stock. Amgen presently has a consensus rating of “Buy” and an average price target of $184.56.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.